The Pathogenesis and Prognostic Factors of Lymphoma

Recruiting

• Conditions: Lymphoma; Hodgkin Lymphoma; Non-hodgkin Lymphoma
• Interventions: Other: Real-world regimen

• Registration Number: NCT06203652
• Lead Sponsor: Shanghai Zhongshan Hospital

Brief Summary

The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.

Detailed Description

Lymphoma is a highly common malignant tumor in Asia. This study aims to observe and describe the clinical and genetic charateristics of Chinese lymphoma patients, and to explore the relationship between those charateristics and pathogenesis and prognostic factors in the real-world population. This study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. The medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors.

Study Timeline

• Study Start: 2023-06-05
• Status Verified: 2024-01
• Study First Submitted: 2024-01-02
• Study First Submitted QC: 2024-01-02
• Last Update Submitted: 2024-01-02
• Study First Posted: 2024-01-12
• Last Update Posted: 2024-01-12
• Primary Completion: 2027-12-31
• Study Completion: 2028-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

• Patients with pathological diagnosis of lymphoma (including Hodgkin lymphoma and non-Hodgkin lyphoma, eg. THRLBCL, DLBCL, MZL, CLL/SLL...) from 2007 to 2027.
• Patients with complete diagnostic, treatment and follow-up records.
• Fully comprehension and signature of the informed consent form (ICF) for participation.

Exclusion Criteria

• Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period.
• Severe mental illness.
• Patients deemed unsuitable for inclusion by the investigator.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
All enrolled patients	Real-world regimen	All patients who are eligible for participation to the study.

Primary Outcome Measures

Name	Time	Method
OS	Baseline up to data cut-off (Up to approximately 20 years)	Overall survival (OS) refers to the time from receiving the first dose to death from any cause

Secondary Outcome Measures

Name	Time	Method
PFS	Baseline up to data cut-off (Up to approximately 20 years)	Progression-free survival (PFS) is defined as the time from the date of first administration to the date of first disease progression or death from any cause, whichever occurs first.

Trial Locations

Locations (1)

Zhongshan Hospital，Fudan University; 🇨🇳 Shanghai, Shanghai, China